Clinical trials of LSD and DMT for depression, PTSD and anxiety — what the evidence says
Clinical trials of LSD and DMT – Psychedelic compounds are re-emerging on the clinical stage as candidates for hard-to-treat mood and trauma disorders. Two of the classic serotonergic agents — LSD (lysergic acid diethylamide) and DMT (N,N-dimethyltryptamine) — have moved from basic neuroscience and anecdote into controlled trials exploring whether brief, supervised dosing can produce sustained improvements in depression, PTSD and anxiety.
Why researchers are interested
Both LSD and DMT act primarily at serotonin 5-HT2A receptors and appear to temporarily reorganize brain network activity, reduce rigid self-referential processing, and open windows for emotional processing and psychological insight. That combination — a pharmacologic ‘reset’ together with therapeutic integration — is the mechanistic rationale for testing them in disorders characterized by entrenched negative patterns (major depression, treatment-resistant depression, PTSD, and some anxiety disorders). Reviews of the field point to changes in connectivity and signal diversity in the brain during psychedelic states as plausible mechanisms for therapeutic benefit.
Clinical trials of LSD and DMT: recent controlled trials and what they found
Interest in LSD has revived after decades of limited research. Recent randomized and dose-ranging trials have looked at single-dose LSD interventions for anxiety and depression, often assessing effects over weeks to months.
-
A multi-center—phase 2-style—trial of a clinical LSD formulation (MM120) evaluated single doses across several dose levels in people with generalized anxiety disorder and related conditions. The trial reported meaningful reductions in anxiety scores and a substantial proportion of participants reaching remission at 12 weeks after a single dose, with the 100-microgram dose often showing the best balance of benefit and tolerability. These findings have been reported in peer-reviewed outlets and press coverage and have sparked follow-on trials.
-
Systematic reviews of recent LSD trials note promising anxiolytic and antidepressant signals, but also call attention to study heterogeneity (differences in dosing, psychotherapy pairing, blinding challenges) and the need for larger, longer randomized trials to confirm durability and safety.
Taken together, LSD data are promising for anxiety and depressive symptoms but still preliminary for routine clinical use; regulators will likely require larger confirmatory trials and clear guidance on therapy integration and safety monitoring.
Clinical trials of LSD and DMT: rapid action and emerging trial evidence
DMT’s pharmacology differs from LSD mainly in kinetics: when inhaled or given intravenously, DMT produces an intense but short-lived psychedelic state (minutes rather than hours). This has made it attractive for designs testing rapid antidepressant effects with briefer in-clinic sessions.
-
Recent phase 2a trials of vaporized/inhaled DMT for treatment-resistant depression report rapid symptom relief in many participants, with some studies showing effects that persist for weeks after a single session. Early results highlight fast onset of antidepressant benefit and a tolerable safety profile in carefully supervised settings. These initial trials are generally small but have stimulated further research into optimal dosing, delivery methods, and how to pair DMT with psychotherapy.
-
Because DMT’s subjective effects are intense but short, researchers are especially focused on integration sessions (post-acute psychotherapy), and on characterizing which patients gain sustained benefit versus those with only transient improvement. Larger randomized trials are underway or planned.
PTSD: where LSD and DMT fit relative to other psychedelics
PTSD research has focused heavily on MDMA and, to a lesser extent, psilocybin; LSD and DMT studies are fewer but growing. Reviews of psychedelic interventions for PTSD note that classic psychedelics may help by enabling emotional engagement with trauma memories in a less threatening way; however, the bulk of controlled evidence in PTSD to date comes from MDMA-assisted psychotherapy trials (which have progressed furthest in late-phase development). LSD and DMT trials for PTSD are still smaller and more exploratory, so while mechanistic plausibility exists, the clinical evidence base remains limited compared with MDMA or psilocybin.
Safety, tolerability and special concerns
Across LSD and DMT trials, common acute effects include perceptual changes, transient anxiety or confusion during the acute experience, nausea (more common with DMT when taken orally as ayahuasca), and transient cardiovascular changes (elevated blood pressure and heart rate). Serious adverse psychiatric events are rare in controlled settings but not impossible — which is why trials use careful screening (excluding people with psychosis or high bipolar risk), medically supervised dosing days, and integration psychotherapy. Critics and reviewers repeatedly emphasize the need for standardized reporting of adverse events and long-term follow-up.
Limitations of the current evidence – Clinical trials of LSD and DMT
Important caveats shape how confidently we can translate trial results into practice:
-
Small samples and heterogeneity: Many studies remain modest in size, use different dosing/psychotherapy models, and mix diagnostic categories. Systematic reviews urge caution about overgeneralizing positive signals until large, multisite RCTs replicate results.
-
Blinding challenges: The striking subjective effects of psychedelics make placebo control and blinding difficult; some trials use active comparators or low-dose controls to address this, but interpretation still requires nuance.
-
Regulatory and logistical hurdles: Scheduling status, need for supervised settings, and training clinicians all slow widescale adoption even if efficacy is proven.
Where the field is headed
The field is rapidly evolving: at academic centers and biotech companies, larger phase 2 and phase 3 programs are in planning or early execution for both LSD and DMT formulations (including defined clinical pharmaceutical products and standardized psychotherapeutic protocols). Researchers are also probing biomarkers (neural connectivity, inflammatory markers) that might predict who benefits most, and refining integration practices that appear central to durable outcomes. If larger trials confirm benefit and acceptable safety, regulators will face decisions about scheduling, clinic standards, training and reimbursement pathways.
Bottom line
Early-to-mid-stage clinical trials of LSD and DMT show encouraging signals for anxiety and depression, and exploratory work continues for PTSD, but the evidence base is still maturing. DMT’s rapid kinetics offer a unique clinical model (shorter in-clinic sessions), while LSD’s longer duration may allow different therapeutic processes. Across both compounds, careful patient selection, supervised administration, and structured psychotherapy/integration are central to safety and likely efficacy. Larger, well-controlled trials with standardized protocols and long-term follow-up are the next essential step before these treatments could become mainstream options.
Key recent sources (for verification and further reading)
-
Omidian H., Clinical Research on Lysergic Acid Diethylamide (LSD) in 2025 (review).
-
UTH / McGovern trial summary: Vaporized DMT Shows Promise for Rapid and Sustained Relief in Treatment-Resistant Depression (May 2025). McGovern Medical School
-
Media summaries and trial coverage of MM120 (LSD formulation) anxiety trial and related academic reporting. Live Science+1
-
Systematic reviews and methodological critiques of psychedelic trials (2023–2025). SAGE Journals+1
